Fosamax and Osteonecrosis of the Jaw: Examining the Causal Link

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Science to Occupational Hazard Assessment

The legacy context of general health and science information has long served as a foundation for public understanding of medication safety and adverse effects. Within this framework, discussions of drug-related risks are typically framed in broad, population-level terms, emphasizing the balance between therapeutic benefits and potential harms. This heritage provides a structured approach to evaluating pharmaceutical safety, relying on established pharmacovigilance principles and clinical observation. Transitioning from this general health perspective, the focus now narrows to a specific occupational exposure concern. In mass production environments, workers may encounter pharmaceutical compounds, including bisphosphonates such as Fosamax, through manufacturing processes. The shift from patient-oriented risk communication to occupational hazard assessment requires careful consideration of exposure pathways, duration, and intensity that differ from therapeutic use. This pivot acknowledges that workplace settings introduce unique variables—such as inhalation of powdered formulations or dermal contact—that may alter risk profiles. The concern centers on whether chronic, low-level occupational exposure to Fosamax could be associated with adverse outcomes, including osteonecrosis of the jaw, a condition previously linked to high-dose therapeutic regimens. This transition maintains the neutral, evidence-informed tone of the legacy context while redirecting attention to the distinct parameters of occupational health surveillance.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the occupational exposure framework, we now examine the specific relationship between Fosamax (alendronate) and osteonecrosis of the jaw (ONJ). Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The drug works by inhibiting bone resorption, thereby increasing bone mass and reducing fracture risk. However, a serious adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw. This condition is characterized by exposed, non-healing bone in the maxillofacial region, often associated with pain, swelling, and infection. Clinical presentation typically involves delayed healing after dental procedures, such as tooth extraction or dental implant placement, and may occur spontaneously (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The diagnosis is based on clinical examination and imaging, with the presence of exposed bone persisting for more than eight weeks in the absence of radiation therapy to the jaws.

Mechanistic Pathways and Evidence

The mechanistic pathways linking Fosamax to ONJ are not fully understood but are believed to involve the drug's potent inhibition of osteoclast activity. Bisphosphonates accumulate in bone, particularly in areas of high turnover such as the jaw, and suppress bone remodeling. This suppression can impair the ability of the jawbone to repair microdamage and respond to local infections or trauma, leading to necrosis. Additionally, bisphosphonates may have anti-angiogenic effects, reducing blood supply to the jawbone. A multiscale characterization of jawbone has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the drug, but a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Risk Factors and Clinical Considerations

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific warning about osteonecrosis of the jaw under section 5.4 (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This warning states that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and that it is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning also notes that ONJ can occur spontaneously (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label for Fosamax Plus D similarly includes a warning with additional details on risk factors and the potential for increased risk with longer exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Causation and Summary

For causation-related considerations, affected patients should be aware that while ONJ is a known adverse effect of bisphosphonates, the absolute risk is low, and the condition is more common in patients with additional risk factors such as cancer, chemotherapy, or poor dental health. The timeline between exposure and documented harm can vary widely, from days to months after starting the drug, and symptoms often resolve after discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, recurrence upon rechallenge suggests a causal relationship in susceptible individuals (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients should maintain good oral hygiene, undergo regular dental check-ups, and inform their dentist about bisphosphonate use before any invasive dental procedures. In summary, Fosamax is associated with osteonecrosis of the jaw, with evidence from clinical reports and mechanistic studies supporting a causal link. The prescribing information includes warnings about this risk, and patients should be monitored for symptoms, especially if they have additional risk factors. The time to onset is variable, and discontinuation of the drug may reduce risk and lead to symptom resolution.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does Fosamax cause osteonecrosis of the jaw?

Yes, Fosamax (alendronate) is associated with osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the jaw. The prescribing information includes a specific warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). While the absolute risk is low, it is a known adverse effect, particularly in patients with additional risk factors such as cancer, chemotherapy, or poor dental health.

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (e.g., tooth extraction, dental implants), diagnosis of cancer, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate use.

How long does it take for ONJ symptoms to appear after starting Fosamax?

The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief after discontinuing the drug, but recurrence may occur upon rechallenge.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.